Strengthening hepatitis B virus clinical research in Africa: the need for multistakeholder collaboration, funding, and political will
The Lancet Microbe · 2026
DOI: 10.1016/j.lanmic.2025.101266 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Lancet Microbe, 2026. Verfasst von Mitchell Leus und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Forum for Collaborative Research, Washington, DC, USA. Hauptthemen laut MEDLINE: Hepatitis B virus, Biomedical Research, Hepatitis B. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health, Bill and Melinda Gates Foundation, European Commission.
Abstract (Originalsprache)
Africa bears a disproportionate burden of hepatitis B virus (HBV) infection, with 68 million chronically infected individuals and 65% of global new infections. However, only 18 (1%) of 1804 global HBV clinical trials have been conducted in Africa, limiting the generalisability of therapeutic findings. The HBV arm of the Forum for Collaborative Research convened a series of multistakeholder discussions between 2023 and 2024, to identify gaps in clinical research and identify solutions. This Personal View synthesises insights from these convenings, highlighting key barriers and potential solutions to the disparities in HBV clinical research. Barriers include inadequate funding, insufficient political will, low community awareness, and logistical challenges due to health-care infrastructure and regulatory systems. This Personal View emphasises the urgent need for African-led research, given region-specific factors such as diverse HBV genotypes and co-infections with HIV and hepatitis D virus. We propose solutions, including strengthening regulatory frameworks, leveraging existing research networks, establishing industry funding consortiums, and advocating for increased investment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The Forum for Collaborative Research, Washington, DC, USA.
- World Hepatitis Alliance, Geneva, Switzerland; African Viral Hepatitis Advisory Group, Abuja, Nigeria; Centre for Initiative and Development (CFID), Taraba State, Nigeria.
- Department of Pediatrics, Ain Shams University, Cairo, Egypt.
- World Hepatitis Alliance, Geneva, Switzerland.
- Hepatitis B Foundation, Doylestown, PA, USA.
- The Francis Crick Institute, London, UK; Division of Infection and Immunity, University College London, London, UK; Department of Infectious Diseases, University College London Hospitals, London, UK.
Förderung
- National Institutes of Health
- Bill and Melinda Gates Foundation
- European Commission
- European and Developing Countries Clinical Trials Partnership
Zitieren
APA
Leus, M., Osakwe, C. E., Adda, D., El-Sayed, M., Hicks, J., Ibrahim, Y., Matthews, P. C., Ndembi, N., Owusu-Ansah, T., Spearman, C. W., Sonderup, M. W., Ward, J., Schaefer, R., & Miller, V. (2026). Strengthening hepatitis B virus clinical research in Africa: the need for multistakeholder collaboration, funding, and political will. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2025.101266
Vancouver
Leus M, Osakwe CE, Adda D, El-Sayed M, Hicks J, Ibrahim Y, et al. Strengthening hepatitis B virus clinical research in Africa: the need for multistakeholder collaboration, funding, and political will. The Lancet Microbe. 2026. doi:10.1016/j.lanmic.2025.101266
BibTeX
@article{Leus2026,
author = {Leus, Mitchell and Osakwe, Chukwunomso E and Adda, Danjuma and El-Sayed, Manal and Hicks, Jessica and Ibrahim, Yasmin and Matthews, Philippa C and Ndembi, Nicaise and Owusu-Ansah, Theobald and Spearman, Catherine Wendy and Sonderup, Mark W and Ward, John and Schaefer, Robin and Miller, Veronica},
title = {Strengthening hepatitis B virus clinical research in Africa: the need for multistakeholder collaboration, funding, and political will},
journal = {The Lancet Microbe},
year = {2026},
doi = {10.1016/j.lanmic.2025.101266}
}
EUVIMED